Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.68 |
| ▸ | S1PR3 | Q99500 | 16/20 | 0.63 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.56 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.56 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13576869 | 0.88 | S1PR1 (0.77) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL1497903 | 0.88 | S1PR1 (0.65) | S1PR1S1PR3 | |
| SCHEMBL1497796 | 0.88 | S1PR1 (0.65) | S1PR1S1PR3 | |
| SCHEMBL1497967 | 0.86 | S1PR1 (0.76) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL5930534 | 0.85 | S1PR1 (0.52) | S1PR1S1PR3 | |
| SCHEMBL688479 | 0.85 | S1PR1 (0.76) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL1497955 | 0.82 | S1PR1 (0.74) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL13614243 | 0.81 | S1PR1 (0.82) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL1497854 | 0.79 | S1PR1 (0.81) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL1497928 | 0.79 | S1PR1 (0.81) | S1PR1S1PR3S1PR4S1PR5S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277194-A1 | AMINOPROPANOL DERIVATIVES | ALBERT RAINER (CH) | 2012-11-01 | — | — | US | disclosed |
| US-20120277194-A1 | AMINOPROPANOL DERIVATIVES | ALBERT RAINER (CH) | 2012-11-01 | — | — | US | disclosed |
| US-20120277194-A1 | AMINOPROPANOL DERIVATIVES | ALBERT RAINER (CH) | 2012-11-01 | — | — | US | disclosed |
| US-20110118210-A1 | AMINOPROPANOL DERIVATIVES | ALBERT RAINER | 2011-05-19 | — | — | US | disclosed |
| US-20110118210-A1 | AMINOPROPANOL DERIVATIVES | ALBERT RAINER | 2011-05-19 | — | — | US | disclosed |
| US-20110118210-A1 | AMINOPROPANOL DERIVATIVES | ALBERT RAINER | 2011-05-19 | — | — | US | disclosed |
| US-7902175-B2 | Aminopropanol derivatives | NOVARTIS AG (CH) | 2011-03-08 | — | — | US | disclosed |
| US-7902175-B2 | Aminopropanol derivatives | NOVARTIS AG (CH) | 2011-03-08 | — | — | US | disclosed |
| US-7902175-B2 | Aminopropanol derivatives | NOVARTIS AG (CH) | 2011-03-08 | — | — | US | disclosed |
| EP-1660449-B1 | AMINOPROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2009-11-18 | — | — | EP | disclosed |
| US-20090156556-A1 | AMINOPROPANOL DERIVATIVES | ALBERT RAINER | 2009-06-18 | — | — | US | disclosed |
| US-20090156556-A1 | AMINOPROPANOL DERIVATIVES | ALBERT RAINER | 2009-06-18 | — | — | US | disclosed |
| US-20090156556-A1 | AMINOPROPANOL DERIVATIVES | ALBERT RAINER | 2009-06-18 | — | — | US | disclosed |
| US-7528120-B2 | Aminopropanol derivatives | NOVARTIS AG (CH) | 2009-05-05 | — | — | US | disclosed |
| US-7528120-B2 | Aminopropanol derivatives | NOVARTIS AG (CH) | 2009-05-05 | — | — | US | disclosed |
| US-7528120-B2 | Aminopropanol derivatives | NOVARTIS AG (CH) | 2009-05-05 | — | — | US | disclosed |
| US-20060264403-A1 | Aminopropanol derivatives | NOVARTIS AG (CH) | 2006-11-23 | — | — | US | disclosed |
| EP-1660449-A1 | AMINOPROPANOL DERIVATIVES | Novartis AG (CH) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005021503-A1 | AMINOPROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118210-A1 | AMINOPROPANOL DERIVATIVES | ADRB1, ADRA1D, ADRA1A | S1PR1 3197/4885S1PR3 2743/4885S1PR4 3844/4885 |
| US-20090156556-A1 | AMINOPROPANOL DERIVATIVES | ADRB1, ADRA1D, ADRA1A | S1PR1 3197/4885S1PR3 2743/4885S1PR4 3844/4885 |
| US-20120277194-A1 | AMINOPROPANOL DERIVATIVES | ADRB1, ADRA1D, ADRA1A | S1PR1 3197/4885S1PR3 2743/4885S1PR4 3844/4885 |
| US-20060264403-A1 | Aminopropanol derivatives | ADRB1, ADRA1D, ADRA1A | S1PR1 3197/4885S1PR3 2743/4885S1PR4 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.